Dyne Therapeutics, Inc.

DYN

$24.49

-1.86%

2026-09-04 09:49:57 EDT-$0.46

Healthcare

Biotechnology

NASDAQ

Active Trading

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE ...

Historical Employee Count of DYN

Current

258

Change

+35.08%

Minimum

Maximum

258

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	258	10-K	Mar 2, 2026	View
Dec 31, 2024	191	10-K	Feb 27, 2025	View
Dec 31, 2023	141	10-K	Mar 5, 2024	View
Dec 31, 2022	123	10-K	Mar 2, 2023	View
Dec 31, 2021	95	10-K	Mar 10, 2022	View

Supply Chain of DYN

Upstream / Downstream / Proxies

Upstream

CDMO Partner 1 (Oligonucleotide Synthesis)CDMO Partner 2 (Antibody/Fab & Bioconjugation)Clinical CRO Partner(s)Third-Party Logistics (3PL) ProviderUniversity of Mons (UMONS)Specialty Raw Material Suppliers (Nucleotide Monomers, Linkers)Cell Culture Media & Bioprocess Suppliers

Downstream

DMD Patients (Exon 51 Amenable) — Future End MarketDM1 Patients — Future End MarketCureDuchenneSpecialty Pharmacy / Distributor (Future, Unselected)

Proxies

Avidity Biosciences, Inc.NASDAQ:RNA Sarepta Therapeutics, Inc.NASDAQ:SRPT Ionis Pharmaceuticals, Inc.NASDAQ:IONS Vertex Pharmaceuticals IncorporatedNASDAQ:VRTX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer